137566-83-7
Chemical Structure
Hexanolamino PAF C-16
Synonym(s): 1-O-Hexa-decyl-2-acetyl-sn-glycero-3-phospho(N,N,N-trimethyl)-hexanolamine
- CAS No.: 137566-83-7
- Formula:C30H62NO7P
- Molecular Weight:579.79
IUPAC Name: (R)-2-acetoxy-3-(hexadecyloxy)propyl (6-(trimethylammonio)hexyl) phosphate
InChIKey: IJAODKNFSHBTDQ-SSEXGKCCSA-N
SMILES: CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCCCCCC[N+](C)(C)C)([O-])=O
Biological Activity: Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Hexanolamino PAF C-16 | 99.9% | Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Newman GE, et al. Utilization by human amniocytes for prostaglandin synthesis of [1-14C]arachidonate derived from 2-[1-14C]arachidonylphosphatidylcholine associated with human fetal pulmonary surfactant. Biochim Biophys Acta. 1993 Mar 10;1176(1-2):106-12. [Content Brief]
- [2]. Grigoriadis G, et al. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity. Br J Pharmacol. 1991 Sep;104(1):171-7. [Content Brief]
Keywords
